Right now, my guess is that people in both organizations are talking a lot less about science. Rather, they are speculating much like I am doing here about their futures. Will I have a job? Will I have to relocate? Will my project be eliminated? In this “Tale of Two Cambridges”, at least for the R&D organization, the “best of times” is not readily apparent.
Pfizer Calms UK Prime Minister, But Rattles R&D For Both AstraZeneca And Itself
Nessun commento:
Posta un commento